Top

Published in:

01-08-2018 | Pericardial Disease (AL Klein, Section Editor)

Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases

Authors: Giacomo Emmi, Maria Letizia Urban, Massimo Imazio, Marco Gattorno, Silvia Maestroni, Giuseppe Lopalco, Luca Cantarini, Domenico Prisco, Antonio Brucato

Published in: Current Cardiology Reports | Issue 8/2018

Abstract

Purpose of Review

This review aims to summarize the role of the interleukin-1 (IL-1) blocking agents in cardiovascular diseases, briefly describing the pathogenetic rationale and the most relevant clinical studies.

Recent Findings

IL-1 is a pivotal cytokine of the innate immune system. Anti-IL-1 agents are currently used for the treatment of several autoimmune and autoinflammatory conditions. Recently, the role of IL-1 has also emerged in cardiovascular diseases. Indeed, two recent randomized controlled trials have shown that the IL-1 receptor antagonist anakinra is effective for the treatment of idiopathic recurrent pericarditis and the IL-1β blocking agent canakinumab is effective in reducing myocardial infarction in people at risk. Interestingly, interfering with IL-1 has proved to be also effective in other cardiovascular manifestations, such as myocarditis, arrhythmias, and heart failure.

Summary

Blocking the IL-1 pathway is a possible new therapeutic strategy, potentially leading to innovative therapies in many acute and chronic cardiovascular diseases.

• Szekely Y, Arbel Y. A review of interleukin-1 in heart disease: where do we stand today? Cardiol Ther. 2018; https://doi.org/10.1007/s40119-018-0104-3. Relevant review focused on the role of IL-1 in heart diseases and potential therapeutic effects of anti-IL-1 treatments.

Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003–18. https://doi.org/10.1016/j.immuni.2013.11.010.CrossRefPubMedPubMedCentral

• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatol Oxf Engl. 2015;54(12):2134–44. https://doi.org/10.1093/rheumatology/kev269. Clinical review highlighting the role of interfering with IL-1 in cardiovascular diseases and type 2 diabetes, conditions that are frequently encountered as co-morbidities in patients with rheumatic diseases. CrossRef

•• Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906–12. https://doi.org/10.1001/jama.2016.15826. First controlled, randomized trial to determine the efficacy of anakinra for colchicine-resistant and corticosteroid-dependent recurrent pericarditis. CrossRefPubMed

•• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914. First controlled randomized double-blind trial to evaluate the efficacy of canakinumab for patients with previous myocardial infarction and a high-sensitivity C-reactive protein. CrossRefPubMed

Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med. 2016;44(8):e751–4. https://doi.org/10.1097/CCM.0000000000001654.CrossRefPubMed

De Jesus NM, Wang L, Lai J, Rigor RR, Francis Stuart SD, Bers DM, et al. Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction. Heart Rhythm. 2017;14(5):727–36. https://doi.org/10.1016/j.hrthm.2017.01.027.CrossRefPubMedPubMedCentral

Van Tassell BW, Raleigh JMV, Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep. 2015;12(1):33–41. https://doi.org/10.1007/s11897-014-0231-7.CrossRefPubMed

Rathinam VAK, Chan FK-M. Inflammasome, inflammation, and tissue homeostasis. Trends Mol Med. 2018;24:304–18. https://doi.org/10.1016/j.molmed.2018.01.004.CrossRefPubMed

10.

Rubartelli A. Redox control of NLRP3 inflammasome activation in health and disease. J Leukoc Biol. 2012;92(5):951–8. https://doi.org/10.1189/jlb.0512265.CrossRefPubMed

11.

Fernandes-Alnemri T, Yu J-W, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458(7237):509–13. https://doi.org/10.1038/nature07710.CrossRefPubMedPubMedCentral

12.

Haneklaus M, O’Neill LAJ, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol. 2013;25(1):40–5. https://doi.org/10.1016/j.coi.2012.12.004.CrossRefPubMed

13.

Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210–5. https://doi.org/10.1038/nri2725.CrossRefPubMed

14.

Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–61. https://doi.org/10.1038/nature08938.CrossRefPubMedPubMedCentral

15.

Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011 Feb 15;123(6):594–604. https://doi.org/10.1161/CIRCULATIONAHA.110.982777.CrossRefPubMed

16.

• Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68(21):2311–28. https://doi.org/10.1016/j.jacc.2016.07.785. Relevant review focused on complicated pericarditis, in particular risk factors, pathogenetic mechanisms, management, and imaging. CrossRefPubMed

17.

Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89–102. https://doi.org/10.1038/nri2691.CrossRefPubMed

18.

Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25(6):469–84. https://doi.org/10.1016/j.smim.2013.10.008.CrossRefPubMedPubMedCentral

19.

Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018 Feb;269:262–71. https://doi.org/10.1016/j.atherosclerosis.2017.12.027.CrossRefPubMed

20.

Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16(8):1000–6. https://doi.org/10.1161/01.ATV.16.8.1000.CrossRefPubMed

21.

Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173(1):57–67. https://doi.org/10.2353/ajpath.2008.070974.CrossRefPubMedPubMedCentral

22.

Portincasa P. Colchicine, Biologic agents and more for the treatment of familial Mediterranean fever. The old, the new, and the rare. Curr Med Chem. 2016;23(1):60–86. https://doi.org/10.2174/0929867323666151117121706.CrossRefPubMed

23.

Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–6. https://doi.org/10.1007/s10067-015-3004-0.CrossRefPubMed

24.

Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380. https://doi.org/10.3389/fphar.2016.00380.CrossRefPubMedPubMedCentral

25.

Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369. https://doi.org/10.3389/fphar.2017.00369.CrossRefPubMedPubMedCentral

26.

Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191–7. https://doi.org/10.1007/s10067-016-3506-4.CrossRefPubMed

27.

• Lazaros G, Antonatou K, Vassilopoulos D. The therapeutic role of interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. Front Med. 2017;4:78. https://doi.org/10.3389/fmed.2017.00078. Clinical review by opinion leaders in the field of treatment of recurrent pericarditis. CrossRef

28.

Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–64. https://doi.org/10.1093/eurheartj/ehv318.CrossRefPubMed

29.

Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009;60(1):264–8. https://doi.org/10.1002/art.24174.CrossRefPubMed

30.

Massardier C, Dauphin C, Eschalier R, Lusson JR, Soubrier M. Resistant or recurrent acute pericarditis: a new therapeutic opportunity? Int J Cardiol. 2014;177(2):e75–7. https://doi.org/10.1016/j.ijcard.2014.09.192.CrossRefPubMed

31.

Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol. 2010;28(5):802.PubMed

32.

Emmi G, Barnini T, Silvestri E, Milco D’Elios M, Emmi L, Prisco D. A new case of idiopathic recurrent acute pericarditis due to R104Q mutation in TNFRSF1A successfully treated with anakinra: expanding the questions. Clin Exp Rheumatol. 2014;32(2):297.PubMed

33.

Camprubí D, Mitjavila F, Arostegui JI, Corbella X. Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant. Int J Rheum Dis. 2017;20(4):510–4. https://doi.org/10.1111/1756-185X.13029.CrossRefPubMed

34.

D’Elia E, Brucato A, Pedrotti P, Valenti A, De Amici M, Fiocca L, et al. Successful treatment of subacute constrictive pericarditis with interleukin-1β receptor antagonist (anakinra). Clin Exp Rheumatol. 2015;33(2):294–5.PubMed

35.

Lazaros G, Vasileiou P, Danias P, Koutsianas C, Vlachopoulos C, Tousoulis D, et al. Effusive-constrictive pericarditis successfully treated with anakinra. Clin Exp Rheumatol. 2015 Dec;33(6):945.PubMed

36.

Schatz A, Trankle C, Yassen A, Chipko C, Rajab M, Abouzaki N, et al. Resolution of pericardial constriction with Anakinra in a patient with effusive-constrictive pericarditis secondary to rheumatoid arthritis. Int J Cardiol. 2016;223:215–6. https://doi.org/10.1016/j.ijcard.2016.08.131.CrossRefPubMed

37.

Finetti M, Insalaco A, Cantarini L, Meini A, Breda L, Alessio M, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014;164(6):1425–1431.e1. https://doi.org/10.1016/j.jpeds.2014.01.065.CrossRefPubMed

38.

Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116(8):1277–9. https://doi.org/10.1016/j.amjcard.2015.07.047.CrossRefPubMed

39.

Imazio M, Brucato A, Pluymaekers N, Breda L, Calabri G, Cantarini L, et al. Recurrent pericarditis in children and adolescents: a multicentre cohort study. J Cardiovasc Med (Hagerstown). 2016;17(9):707–12. https://doi.org/10.2459/JCM.0000000000000300.CrossRef

40.

Lazaros G, Vasileiou P, Koutsianas C, Antonatou K, Stefanadis C, Pectasides D, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014;73(12):2215–7. https://doi.org/10.1136/annrheumdis-2014-205990. CrossRefPubMed

41.

Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F, et al. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. 2016;34(3):531–8.PubMed

42.

Emmi G, Silvestri E, Squatrito D, Vitale A, Bacherini D, Vannozzi L, et al. Long-term efficacy and safety of anakinra in a patient with Behçet’s disease and concomitant tuberculosis infection. Int J Dermatol. 2017;56(2):218–20.CrossRefPubMed

43.

Emmi G, Silvestri E, Cantarini L, Lopalco G, Cecchi L, Chiarini F, et al. Rapid desensitization to anakinra-related delayed reaction: need for a standardized protocol. J Dermatol. 2017;44(8):981–2. https://doi.org/10.1111/ijd.13337. CrossRefPubMed

44.

Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117(20):2662–9. https://doi.org/10.1161/CIRCULATIONAHA.107.731877.CrossRefPubMed

45.

Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438. https://doi.org/10.1371/journal.pone.0033438.CrossRefPubMedPubMedCentral

46.

• Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol. 2016;67(6):544–51. https://doi.org/10.1097/FJC.0000000000000378. Interesting randomized, double-blinded, placebo-controlled pilot study to evaluate the role of anakinra in blocking acute inflammatory response during acute decompensated heart failure. CrossRefPubMedPubMedCentral

47.

Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113(2):321–7. https://doi.org/10.1016/j.amjcard.2013.08.047.CrossRefPubMed

48.

Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, Dixon DL, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol. 2017;40(9):626–32. https://doi.org/10.1002/clc.22719.CrossRefPubMedPubMedCentral

49.

Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017;10(11):e004373. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004373. CrossRefPubMed

50.

Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res. 2016;167(1):152–66. https://doi.org/10.1016/j.trsl.2015.07.002.CrossRefPubMed

51.

Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619–28. https://doi.org/10.1161/CIRCIMAGING.113.001193.CrossRefPubMed

52.

Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105(10):1371–1377.el. https://doi.org/10.1016/j.amjcard.2009.12.059.CrossRefPubMed

53.

Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–400. https://doi.org/10.1016/j.amjcard.2013.01.287.CrossRefPubMedPubMedCentral

54.

• Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115(3):288–92. https://doi.org/10.1016/j.amjcard.2014.11.003. Valuable patient-level pooled analysis on 40 patients from two previous pilot studies, showing that anakinra may prevent new-onset heart failure after STEMI at a long-term follow-up. CrossRefPubMed

55.

• Morton AC, Rothman AMK, Greenwood JP, Gunn J, Chase A, Clarke B, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–84. https://doi.org/10.1093/eurheartj/ehu272. Interesting phase II, double-blinded, randomized, placebo-controlled trial showing the importance of anakinra in reducing inflammatory markers in acute coronary syndromes. CrossRefPubMed

56.

Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016;91:114–22. https://doi.org/10.1016/j.yjmcc.2015.12.024.CrossRefPubMed

57.

Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol. 2015;42(3):421–8. https://doi.org/10.3899/jrheum.140861.CrossRefPubMed

58.

Pisoni CN, Reina S, Arakaki D, Eimon A, Carrizo C, Borda E. Elevated IL-1β levels in anti-Ro/SSA connective tissue diseases patients with prolonged corrected QTc interval. Clin Exp Rheumatol. 2015;33(5):715–20.PubMed

59.

Cheng T, Wang X-F, Hou Y-T, Zhang L. Correlation between atrial fibrillation, serum amyloid protein A and other inflammatory cytokines. Mol Med Rep. 2012;6(3):581–4. https://doi.org/10.3892/mmr.2012.934.CrossRefPubMed

60.

Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–48. https://doi.org/10.1161/CIRCULATIONAHA.112.122556.CrossRefPubMed

61.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet Lond Engl. 2018;391(10118):319–28. https://doi.org/10.1056/NEJMoa1707914.CrossRef

62.

•• Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2017;390(10105):1833–42. https://doi.org/10.1016/S0140-6736(17)32247-X. Intriguing exploratory analysis on the reduction of mortality by lung cancer after blockade of interleukin-1β pathway. CrossRef

63.

Neri Serneri GG, Prisco D, Martini F, Gori AM, Brunelli T, Poggesi L, et al. Acute T-cell activation is detectable in unstable angina. Circulation. 1997;95(7):1806–12.CrossRefPubMed

64.

Neri Serneri GG, Boddi M, Modesti PA, Cecioni I, Coppo M, Papa ML, et al. Immunomediated and ischemia-independent inflammation of coronary microvessels in unstable angina. Circ Res. 2003;92(12):1359–66. https://doi.org/10.1161/01.RES.0000079025.38826.E1.CrossRefPubMed

65.

Becatti M, Marcucci R, Bruschi G, Taddei N, Bani D, Gori AM, et al. Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014;34(7):1355–61. https://doi.org/10.1161/ATVBAHA.114.303785.CrossRefPubMed

66.

•• Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation. 2016;133(3):302–11. https://doi.org/10.1161/CIRCULATIONAHA.115.017738. Important evidence that altered fibrinogen structure and impaired fibrinogen function are associated with neutrophil activation and enhanced reactive oxygen species production, suggesting a link between inflammation and thrombosis in systemic vasculitis. PubMedCrossRef

67.

Van Tassell BW, Varma A, Salloum FN, Das A, Seropian IM, Toldo S, et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol. 2010;55(2):117–22. https://doi.org/10.1097/FJC.0b013e3181c87e53.CrossRefPubMed

68.

Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–91. https://doi.org/10.1093/eurheartj/ehu203.CrossRefPubMedPubMedCentral

Title: Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases
Authors: Giacomo Emmi
Maria Letizia Urban
Massimo Imazio
Marco Gattorno
Silvia Maestroni
Giuseppe Lopalco
Luca Cantarini
Domenico Prisco
Antonio Brucato
Publication date: 01-08-2018
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 8/2018
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-018-1007-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2018

HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity

Cardiovascular Autonomic Dysfunction in Patients with Cancer

Gender Disparities in Presentation, Management, and Outcomes of Acute Myocardial Infarction

Long-term Management of the Arterial Switch Patient

Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page